RxDoctor Payments DataLook up a doctor →

Prashant Patel, MD

Sleep Medicine · Bridgewater, NJNPI 1982806915

Payments from drug & device makers

$19,937in general payments, 2019–2025

Across 1,006 payments — averaging $19.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$5K
  • GSK$2K
  • AstraZeneca$2K
  • Philips North America LLC$1K
  • Mylan Specialty L.p.$800
  • Boehringer Ingelheim$780
  • plus $8K from 39 others

What the payments were for

  • Speaking & faculty fees$5,17526%
  • Food & beverage$14,52773%
  • Education$2351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,937 in reported general payments places this provider in the 95th percentile of 40 sleep medicine providers in New Jersey.

See all sleep medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$263,618
Medicare patients
470
Services billed
3,795

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate37$620,885
Trelegy ElliptaFluticasone/Umeclidin/Vilanter320$308,660
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr128$79,080
Breo ElliptaFluticasone/Vilanterol146$71,653
Breztri AerosphereBudesonide/Glycopyr/Formoterol75$50,757
Stiolto RespimatTiotropium Br/Olodaterol Hcl46$29,548
Spiriva RespimatTiotropium Bromide22$16,625
DuleraMometasone/Formoterol13$6,769
Fluticasone-SalmeterolFluticasone Propion/Salmeterol32$6,725
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate23$6,592
Tudorza PressairAclidinium Bromide13$6,555
Spiriva HandihalerTiotropium Bromide11$5,208
Albuterol Sulfate HfaAlbuterol Sulfate149$4,914
SymbicortBudesonide/Formoterol Fumarate16$4,312
Roflumilast32$4,266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$780$667,058105 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$2,187$459,393594 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,617$55,06991 claims
MerckDulera$71$6,76913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 40 sleep medicine providers in New Jersey.

Other sleep medicine in Bridgewater

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →